Pharmosa Biopharm Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Pei Kan
Chief executive officer
NT$6.0m
Total compensation
| CEO salary percentage | 77.63% |
| CEO tenure | 8yrs |
| CEO ownership | 2.0% |
| Management average tenure | 4yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -NT$238m |
| Jun 30 2025 | n/a | n/a | -NT$282m |
| Mar 31 2025 | n/a | n/a | -NT$207m |
| Dec 31 2024 | NT$6m | NT$5m | -NT$167m |
| Sep 30 2024 | n/a | n/a | -NT$293m |
| Jun 30 2024 | n/a | n/a | NT$28m |
| Mar 31 2024 | n/a | n/a | NT$19m |
| Dec 31 2023 | NT$5m | NT$4m | NT$8m |
Compensation vs Market: Pei's total compensation ($USD190.71K) is above average for companies of similar size in the TW market ($USD142.76K).
Compensation vs Earnings: Pei's compensation has increased whilst the company is unprofitable.
CEO
Pei Kan
Dr. Pei Kan, Ph.D. is President, General Manager at Pharmosa Biopharm Inc. Dr. kan serves as Director at Pharmosa Biopharm Inc since January 22, 2018. Dr. Kan graduated from National Tsinghua University in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | NT$6.04m | 2.05% NT$ 123.5m | |
| Vice President of Operations | 9.3yrs | NT$4.16m | 0.45% NT$ 27.0m | |
| Vice President of Administration | 4yrs | NT$3.47m | 0.035% NT$ 2.1m | |
| Senior Director of Strategic & Project Development Division | 3.3yrs | NT$3.06m | no data | |
| Senior Director of Process Development Division | 3.3yrs | NT$3.56m | no data | |
| Vice President of Finance & Accounting | 10.6yrs | no data | no data |
Experienced Management: 6875's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8yrs | NT$6.04m | 2.05% NT$ 123.5m | |
| Director | 4.3yrs | NT$412.00k | no data | |
| Independent Director | no data | NT$622.00k | 0.043% NT$ 2.6m | |
| Independent Director | 4yrs | NT$622.00k | no data | |
| Independent Director | 4yrs | NT$622.00k | no data | |
| Representative Vice Chairman | 9.6yrs | NT$1.72m | 0.69% NT$ 41.9m | |
| Representative Chairman | 9.6yrs | NT$3.24m | no data |
Experienced Board: 6875's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 02:06 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmosa Biopharm Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.